Chinese clinical oncology最新文献

{"title":"A narrative review of the value of immunoinflammatory markers in the prognosis of endometrial carcinoma.","authors":"Xinxin Yin, Haoyang Zhang, Sai Zhang","doi":"10.21037/cco-2026-1-0011","DOIUrl":"10.21037/cco-2026-1-0011","url":null,"abstract":"<p><strong>Background and objective: </strong>Endometrial cancer (EC), a prevalent gynecological malignancy, poses a significant threat to women's health, rendering prognosis assessment a pivotal area of clinical research. In recent years, immune-inflammatory markers have garnered increasing attention for their potential in predicting tumor prognosis. This paper comprehensively reviews the significance of immune-inflammatory markers in determining the prognosis of EC.</p><p><strong>Methods: </strong>We conducted a narrative review. Relevant literature was identified through searches in PubMed and Web of Science (January 1, 2000 to July 31, 2025). Key search terms included \"endometrial neoplasms\", \"prognosis\", \"biomarkers\", \"neutrophils\", \"lymphocytes\", \"tumor microenvironment\", \"tumor-infiltrating lymphocytes\", and \"immune checkpoint inhibitors\". Studies were critically appraised with attention to study design, timing of marker assessment, cutoff definitions, adjustment for confounders, and clinical endpoints [e.g., overall survival (OS), progression-free survival (PFS)].</p><p><strong>Key content and findings: </strong>Elevated peripheral blood indices [e.g., neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII)] are consistently associated with advanced stage, aggressive histology, and independently predict poorer overall and recurrence-free survival in multiple cohorts. Findings indicate that these markers are not only intricately linked to the onset and development of EC but also hold substantial value in predicting prognostic factors like tumor recurrence, metastasis, and patient survival rates. For instance, elevated NLR and PLR levels are frequently associated with more advanced tumor stages, unfavorable histological grades, and poorer prognoses. Immune-inflammatory markers can effectively mirror the body's immune state and the intensity of the inflammatory response. We summarize this evidence in structured tables, highlighting cut-off values, multivariate analysis results, and measurement timing. Emerging data on novel markers like osteopontin are also discussed. However, significant heterogeneity exists in cutoff values, and these markers are susceptible to confounders such as infection and metabolic conditions.</p><p><strong>Conclusions: </strong>Immunoinflammatory markers provide valuable, complementary prognostic information in EC. Standardization of assay timing, cutoff values, and integration into multivariable models that include established factors (stage, grade) is required before routine clinical implementation. Future research should focus on validating these markers in prospective trials and integrating them with molecular classifiers to build robust, personalized prognostic models.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 2","pages":"35"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147962597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benign metastasizing leiomyoma: a systematic review of diagnosis, management, and outcomes.","authors":"Karolina Karoń, Natalia Szczęsny, Krzysztof Piątkowski, Ewelina Bornio, Wojciech Grabowski, Hanna Plata, Monika Pałatyńska, Łukasz Karoń, Szymon Piątek","doi":"10.21037/cco-25-40","DOIUrl":"10.21037/cco-25-40","url":null,"abstract":"<p><strong>Background: </strong>Benign metastasizing leiomyoma (BML) is a rare complication of uterine fibroids, in which benign smooth muscle tumors spread to distant sites. Due to its rarity, clinical presentation and management remain insufficiently defined. This systematic review provides a comprehensive overview of BML. This study aimed to assess the clinical characteristics, treatment methods, and outcomes of patients with BML.</p><p><strong>Methods: </strong>The review included case reports and case series. A literature search was conducted in Google Scholar and PubMed using the keyword \"benign metastasizing leiomyoma\" from January 1, 2000 until March 31, 2024, yielding 310 articles from Google Scholar and 468 from PubMed. After removing duplicates and screening titles and abstracts, 213 articles were included. Data were systematically extracted on patient demographics, menopausal status, surgical history, tumor characteristics, imaging studies, histopathology, genetic tests, treatment methods and survival outcomes.</p><p><strong>Results: </strong>The mean age was 47.8 years, and 89 (32.1%) patients were asymptomatic. The most common symptoms were: cough (n=55, 29.3%), dyspnea (n=52, 27.7%) and abdominal pain (n=42, 22.3%). Metastatic lesions were primarily found in the lungs (n=235, 84.8%), followed by the peritoneum (n=40, 14.4%), vertebrae (n=17, 6.1%) and heart (n=15, 5.4%). Total and subtotal hysterectomy was performed in 180 (75.3%) and 26 (10.9%) patients, respectively. The majority of patients (n=239, 86.3%) underwent surgery, performed before BML diagnosis in 200 cases (83.7%) and after diagnosis in 39 cases (16.3%). The mean time between surgery and the diagnosis of BML was 101 months. The most common positive receptor expressions were for estrogen (n=181, 65.3%), progesterone (n=178, 64.3%) and desmin (n=129, 46.6%). Adjuvant treatment included predominant use of hormonal agents (n=82, 29.6%), while chemotherapy was rare (n=3, 3.8%). The mean follow-up was 18 months. Among the eight patients (2.9%) who died from BML progression, the disease was the direct cause of death in three (37.5%) cases.</p><p><strong>Conclusions: </strong>BML is a rare complication of uterine fibroids characterized by frequent pulmonary metastases, hormone receptor positivity, and variable clinical course. Hormonal therapy is the mainstay of adjuvant treatment, but disease progression and death can occur, highlighting the importance of individualized management and follow-up.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 2","pages":"37"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147961792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TP63 drives TKI resistance in EGFR-mutant lung cancer via ferroptosis inhibition.","authors":"Kehan Li, Jiane Liu, Wenjuan Wang, Guangmin Zhang, Lina Zhu, Linlin Liu, Xiaohui Xu","doi":"10.21037/cco-2025-aw-151","DOIUrl":"10.21037/cco-2025-aw-151","url":null,"abstract":"<p><strong>Background: </strong>The emergence of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) presents a significant obstacle in the therapeutic strategy for EGFR-mutant non-small cell lung cancer (NSCLC). While secondary mutations explain some cases, adaptive resistance mechanisms involving lineage plasticity and metabolic rewiring are increasingly recognized but poorly understood. This study aimed to investigate the role of the transcription factor TP63 in mediating adaptive resistance to EGFR-TKIs, with a focus on its potential regulation of ferroptosis.</p><p><strong>Methods: </strong>To investigate these mechanisms, we generated osimertinib-resistant derivatives of EGFR-mutant PC9 and HCC827 cell lines. We utilized short hairpin RNA (shRNA) interference to silence TP63 and performed functional assays including cell viability, colony formation, wound-healing, and transwell invasion assays. Mechanistic insights were gained through integrated RNA sequencing (RNA-seq), immunofluorescence, and lipid peroxidation assays using BODIPY 581/591 C11.</p><p><strong>Results: </strong>We identified the transcription factor TP63 as a master regulator of adaptive resistance, showing marked upregulation in resistant cells. Although TP63 depletion did not affect basal cell viability, its loss significantly restored sensitivity to osimertinib, suppressing proliferation, clonogenic growth, and invasive potential. Transcriptomic and biochemical analyses revealed that TP63 maintains redox homeostasis by transcriptionally activating GPX4 and antioxidant gene networks. Consequently, TP63 silencing collapsed this defense system, leading to the accumulation of lipid peroxides and inducing ferroptotic cell death under drug pressure.</p><p><strong>Conclusions: </strong>Clinically, high TP63 expression correlates with reduced overall survival in EGFR-mutant NSCLC patients. These findings define a critical TP63-GPX4 ferroptosis axis that safeguards tumor cell survival during therapeutic stress, highlighting ferroptosis induction as a potential therapeutic strategy to overcome EGFR-TKI resistance.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 2","pages":"30"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147962434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical management of pancreatic cancer: an overview.","authors":"Daniel Chun Pong Kwok, Kenneth Siu Ho Chok","doi":"10.21037/cco-25-86","DOIUrl":"10.21037/cco-25-86","url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma (PDAC) is notorious for its aggressive tumour biology as well as its generally poor prognosis despite advances in systemic treatment. Oncological surgery with curative intent remains the hope for a potential cure for patients with pancreatic cancer. Apart from the usual tumour classification based on primary tumour, regional lymph nodal, and distant metastasis (TNM) staging, pancreatic cancer is also categorised into resectable, borderline resectable and locally advanced based on the anatomical relationship of the tumour with the adjacent important vasculature, namely superior mesenteric artery (SMA) and superior mesenteric vein (SMV), celiac trunk, common hepatic artery (CHA), portal vein (PV) to decide on resectability. The anatomical location of the pancreatic tumour and its extent decide the option of surgery, usually pancreaticoduodenectomy for head and uncinate tumours, whereas distal pancreatectomy for tumours in the body or tail. Sometimes, total pancreatectomy is indicated for extensive infiltrative tumours or multifocal tumours to achieve a negative resection margin. Variations in surgical techniques have been described to reduce the complications, e.g., postoperative pancreatic fistula (POPF), and the related morbidity or even mortality. However, no single technique has been shown to be consistently superior to the others in the literature. To further improve the resection margin clearance, extended resection techniques, namely radical antegrade modular pancreatosplenectomy (RAMPS), distal pancreatectomy with celiac axis resection (DP-CAR) (also known as modified Appleby procedure), were also described, but the benefit on overall survival is yet to be proven. For patients with unresectable or locally advanced pancreatic tumour, sometimes surgical bypass with palliative intent could be performed to relieve the biliary or duodenal obstruction. There is a potential role of tumour ablative therapy, either by thermal energy or non-thermal [e.g., irreversible electroporation (IRE), radiofrequency ablation, or microwave ablation], for local tumour control; however, evidence is still limited to conclude its value. Management of PDAC is often challenging for the surgeon and very often necessitates a multidisciplinary meeting for conjoint decision and collaboration for subsequent tailored management.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 2","pages":"33"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147962391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting metabolism in acute myeloid leukemia: the next therapeutic frontier?","authors":"Alain Mina, Amer M Zeidan","doi":"10.21037/cco-2025-1-191","DOIUrl":"https://doi.org/10.21037/cco-2025-1-191","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 2","pages":"24"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147962377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing precision oncology through innovative and adaptive master protocol designs: statistical, operational, and regulatory perspectives.","authors":"Jun Yin, Susan Geyer, Qian Shi, Bryan McComb, Courtney Henry, Jonathan Metts","doi":"10.21037/cco-2025-aw-153","DOIUrl":"10.21037/cco-2025-aw-153","url":null,"abstract":"<p><p>Master protocol trials-including basket, umbrella, and platform designs-have revolutionized precision oncology by enabling the simultaneous evaluation of multiple therapies, biomarkers, and tumor subtypes within a unified adaptive framework. They operationalize the core vision of precision oncology-delivering the right therapy to the right patient efficiently-through harmonized infrastructure and adaptive statistical learning. These designs can improve statistical efficiency and operational feasibility by sharing infrastructure, controls, and information across related substudies. However, their benefits are not automatic and depend critically on the rigor of implementation, calibration, and governance. In this review, we synthesize recent methodological, operational, and regulatory advances in master protocol design, with a focus on how these elements jointly enable reliable inference in molecularly heterogeneous oncology settings. Recent statistical innovations have enhanced information sharing across related cohorts while maintaining control of false-positive results under clinical heterogeneity. Platform trials may extend these principles through multi-stage calibration and latent-subgroup dose optimization, providing flexibility for adding or dropping arms while preserving inferential rigor. By explicitly examining the trade-offs, limitations, and practical constraints underlying these designs, this review clarifies when and how master protocols can fulfill their promise in precision oncology. Collectively, these advances establish master protocol trials as powerful and efficient engines for precision oncology, capable of integrating hierarchical modeling, adaptive learning, and real-world data to accelerate therapeutic discovery and regulatory translation. With continued progress in assay standardization, real-time data infrastructure, and adaptive governance, master protocols are poised to transform clinical development, advancing precision oncology from concept to scalable, executable reality.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 2","pages":"40"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147962587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances and applications of liquid biopsy approaches in hepatopancreatobiliary (HPB) cancers: a literature review.","authors":"Dina Hauptschein, Pedro Luiz Serrano Uson Junior, Mitesh J Borad","doi":"10.21037/cco-2025-aw-135","DOIUrl":"10.21037/cco-2025-aw-135","url":null,"abstract":"<p><strong>Background and objective: </strong>Hepatopancreatobiliary (HPB) cancers, including pancreatic ductal adenocarcinoma (PDAC), hepatocellular carcinoma (HCC), and cholangiocarcinoma (CCA), are among the deadliest malignancies due to late-stage diagnosis and limited curative options. Conventional tissue biopsies are often invasive and insufficient for longitudinal monitoring. This review synthesizes the current available literature on liquid biopsy, a minimally invasive approach that uses analysis of circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA) in serum, plasma, or bile, to enable better early detection, surveillance, and treatment monitoring of HPB cancers.</p><p><strong>Methods: </strong>A search of PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Scopus, and Google Scholar identified peer-reviewed studies published between April 2016 and July 2025 using the key terms \"liquid biopsy\", \"ctDNA\", \"cfDNA\", \"pancreatic\", \"hepatobiliary\", \"liver\", \"cholangiocarcinoma\", and \"gallbladder\", combined with \"early detection\", \"screening\", \"surveillance\", \"minimal residual disease\", and \"monitoring\". Preprints, conference abstracts, and editorials were excluded, and no language restrictions were applied. Fifty-eight studies met the inclusion criteria.</p><p><strong>Key content and findings: </strong>Recent studies report strong diagnostic performance for early-stage disease, with sensitivities ranging from 63% to 91% and area under the curve (AUC) values often exceeding 0.90 using next-generation sequencing (NGS), methylation profiling, and fragmentomics. Liquid biopsy has also demonstrated improved identification and detection of cancer-specific gene markers. Significant improvements in early detection and prognostication have been shown for PDAC with KRAS, TP53, SMAD4, and cfDNA methylation panels, and for CCA with FGFR2, IDH1/2, and BAP1 mutations detected in bile-derived cfDNA. In HCC, alterations in TERT promoter, TP53, CTNNB1, along with methylation markers such as RASSF1A, APC, and GSTP1, have predicted early disease and recurrence. Longitudinal ctDNA profiling further enables monitoring of minimal residual disease (MRD) and therapeutic resistance.</p><p><strong>Conclusions: </strong>Liquid biopsy provides a powerful, minimally invasive tool for early detection, MRD assessment, and real-time disease monitoring in HPB cancers. Despite promising results, broader clinical adoption is limited by assay variability and the need for standardization and prospective validation. Continued innovation and large-scale studies may establish liquid biopsy as a transformative tool for early detection and personalized management of HPB cancers.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 2","pages":"38"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147962633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is rechallenge with CDK4/6 inhibitors beyond progression reasonable for patients with hormone receptor-positive and HER2-negative advanced breast cancer?-a commentary on the PALMIRA trial.","authors":"Mai Shimura, Toru Mukohara","doi":"10.21037/cco-2025-aw-139","DOIUrl":"https://doi.org/10.21037/cco-2025-aw-139","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 2","pages":"27"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147962415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short- and long-term outcomes after laparoscopic versus open total gastrectomy for stage 0-I gastric cancer: a multicenter, retrospective analysis.","authors":"Fangyao Zhou, Zaisheng Ye, Chengbin Zheng, Zhaojun Zhang, Wenjun Xiong, Junjiang Wang, Weixian Hu, Jiabin Zheng, Bin Luo, Wei Wang, Yong Li, Luchuan Chen, Xingyu Feng","doi":"10.21037/cco-2025-aw-152","DOIUrl":"10.21037/cco-2025-aw-152","url":null,"abstract":"<p><strong>Background: </strong>Laparoscopic surgery has been increasingly adopted in the treatment of gastric cancer. Although the safety and efficacy of laparoscopic distal gastrectomy have been well established, evidence regarding laparoscopic total gastrectomy (LTG) remains limited, especially for early-stage disease. This study aimed to compare the short-term surgical outcomes and long-term survival between LTG and open total gastrectomy (OTG) in patients with stage 0-I gastric cancer.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinicopathological data of 122 patients with stage 0-I gastric cancer underwent radical LTG or OTG from January 2010 to December 2013. Multivariate regression with a generalized estimation equation (GEE) was used to analyze the differences in total complications, LTG-related complications and OTG-related complications between the laparoscopic and open groups. The inverse probability of treatment weighting (IPTW) Kaplan-Meier survival curve was used to compare the long-term survival of the two groups. The primary outcome was the short-term outcomes and long-term survival of LTG with traditional OTG for stage 0-I gastric cancer.</p><p><strong>Results: </strong>The incidence of postoperative complications was 16.4% in the LTG group and 18.4% in the OTG group, with no statistically significant difference between the two groups (P>0.05). In the adjusted multivariate GEE regression for OTG-related complications, the risk of OTG-related complications in the laparoscopic group was 0.111 (95% confidence interval: 0.016-0.771, P=0.03). Before and after IPTW adjustment, there was no statistically significant difference in survival between the LTG group and the OTG group (P=0.28 and P=0.34).</p><p><strong>Conclusions: </strong>LTG is safe and feasible to apply in stage 0-I gastric cancer. Comparing OTG, LTG with a similar overall complication rate and long-term survival, but reduce the incidence of OTG-related complications and does not increase the risk of LTG-related complications in stage 0-I gastric cancer. However, these findings still need to be confirmed in a large clinical trial.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 2","pages":"29"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147962359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-line fulvestrant vs. anastrozole in hormone receptor-positive advanced breast cancer: insights from the final FALCON trial results.","authors":"Yuko Takahashi, Shogo Nakamoto, Maki Tanioka, Tadahiko Shien","doi":"10.21037/cco-2025-1-175","DOIUrl":"https://doi.org/10.21037/cco-2025-1-175","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"15 2","pages":"22"},"PeriodicalIF":2.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147962169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}